Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers

Miloslav Klugar 1,2,†, Abanoub Riad 1,3,†, Mohamed Mekhemar 4,†, Jonas Conrad 4, Mayte Buchbender 5,†, Hans-Peter Howaldt 6 and Sameh Attia 6,*

1 Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC; JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic; klugar@med.muni.cz (M.K.); abanoub.riad@med.muni.cz (A.R.)
2 Institute of Health Information and Statistics of the Czech Republic, Palackého náměstí 4, 128 01 Prague, Czech Republic
3 Department of Public Health, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
4 Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, Kiel University, Arnold Heller Str. 3, Haus B, 24105 Kiel, Germany; mekhemar@konspar.uni-kiel.de (M.M.); conrad@konspar.uni-kiel.de (J.C.)
5 Department of Oral and Maxillofacial Surgery, University of Erlangen-Nuremberg, Glückstraße 11, 91054 Erlangen, Germany; mayte.buchbender@uk-erlangen.de
6 Department of Oral and Maxillofacial Surgery, Justus-Liebig-University, Klinikstrasse 33, 35392 Giessen, Germany; HP.Howaldt@uniklinikum-giessen.de
† Correspondence: sameh.attia@dentist.med.uni-giessen.de
* Equal contribution as first authorship.

Abstract: Background: the increasing number of COVID-19 vaccines available to the public may trigger hesitancy or selectivity towards vaccination. This study aimed to evaluate the post-vaccination side effects of the different vaccines approved in Germany; Methods: a cross-sectional survey-based study was carried out using an online questionnaire validated and tested for a priori reliability. The questionnaire inquired about demographic data, medical and COVID-19-related anamneses, and local, systemic, oral, and skin-related side effects following COVID-19 vaccination; Results: out of the 599 participating healthcare workers, 72.3% were females, and 79.1% received mRNA-based vaccines, while 20.9% received a viral vector-based vaccine. 88.1% of the participants reported at least one side effect following the COVID-19 vaccination. The mRNA-based vaccines were associated with a higher prevalence of local side effects (e.g., injection site pain), while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (e.g., headache/fatigue). The vast majority (84.9%) of side effects resolved within 1–3 days after vaccination, which are promising results from a safety point of view for both types of vaccines. This study is one of the few studies that aims to enhance our emerging knowledge about the risk factors of COVID-19 vaccines side effects by inquiring and analyzing the self-reported side effects across various demographic and medical parameters.

Simple Summary: The main way to overcome the COVID-19 pandemic is mass vaccination of the public. However, the public’s vaccine hesitancy toward the available vaccines is a big challenge in the fighting against the coronavirus spreading. We aimed in this study to report for the first time the short-term side effects following mRNA-based (Pfizer-BioNTech and Moderna) and viral vector-based (AstraZeneca) COVID-19 vaccines among German healthcare workers. A survey-based study was conducted through an online validated questionnaire. Overall, 88.1% of the German healthcare workers included in this study reported at least one side effect following the COVID-19 vaccination. The mRNA-based vaccines were associated with a higher prevalence of local side effects (e.g., injection site pain), while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (e.g., headache/fatigue). The vast majority (84.9%) of side effects resolved within 1–3 days after vaccination, which are promising results from a safety point of view for both types of vaccines. This study is one of the few studies that aims to enhance our emerging knowledge about the risk factors of COVID-19 vaccines side effects by inquiring and analyzing the self-reported side effects across various demographic and medical parameters.
with a higher prevalence of systemic side effects (87.2% vs. 61%; Sig. < 0.001). Females and the younger age group were associated with an increased risk of side effects either after mRNA-based or viral vector-based vaccines. The gender- and age-based differences warrant further rigorous investigation and standardized methodology.

**Keywords:** adverse effects; BTN162 vaccine; ChAdOx1 COVID-19 vaccine; cross-sectional studies; COVID-19 vaccines; drug-related side effects and adverse reactions; Germany; health personnel; mRNA-1273 vaccine; prevalence

1. **Introduction**

Since the spreading of the COVID-19 pandemic, its influence has become evident worldwide in all disciplines and sectors, e.g., social, financial, and health sectors, etc. We were clearly unprepared for such a circumstance, which was entirely unfamiliar to the current generation. Over time, it was clear that overcoming this pandemic can only be done through mass vaccination [1].

Vaccination against infectious diseases such as SARS-CoV-2 is the most cost-effective public health intervention. In addition to individual immunization, the achievement of collective protection (so-called community immunity) for the majority of vaccine-preventable infections is also crucial to protect vulnerable groups in the population who, for various reasons, cannot be vaccinated [2].

The currently available vaccines against SARS-CoV-2 are manufactured by one of the following technologies: (a) mRNA-based vaccines, (b) viral vector-based vaccines, (c) protein subunit vaccines, and (d) whole virus or inactivated virus vaccines [3]. Therefore, the European Medicines Agency (EMA) has approved vaccines that only belong to the first two technologies (mRNA-based and viral vector-based vaccines), which aim to produce spike protein-specific antibodies [4]. The mRNA-based technology is relatively novel in vaccine industry, and it employs molecular templates of messenger RNA (mRNA) to deliver the genetic information to produce the spike (S) glycoprotein antigen, not to deliver the antigen itself [5]. The viral vector-based vaccines against SARS-CoV-2 use a non-replicating harmless version of adenovirus as a vehicle to deliver the genetic code of the S glycoprotein antigen, thus eliciting the targeted immune response [6].

In Germany, a country with a population of around 84 million, 3,729,682 COVID-19 cases with 91,007 deaths were reported by 1 July 2021 [7,8]. To date, four COVID-19 vaccines had been approved in Germany; Pfizer-BioNTech (mRNA-based vaccine) approved since 21 December 2020, Moderna (mRNA-based vaccine) approved since 6 January 2021, AstraZeneca-Oxford (viral vector-based vaccine) approved since 29 January 2021, and Janssen (viral vector-based vaccine) approved since 11 March 2021 [9].

On 1 July 2021, 926,463 vaccine doses were administered in Germany, leading to 31,487,487 people (37.9% of the total population) being fully vaccinated and 46,249,449 people (55.6%) receiving at least one vaccine dose [10]. The German government imported -to date- 57,619,463 doses of Pfizer-BioNTech, 13,869,863 doses of AstraZeneca-Oxford, 7,641,280 doses of Moderna, and 2,893,697 doses of Janssen [10,11]. The Germany’s vaccination strategy prioritized healthcare workers to receive the vaccine, especially those who worked in the frontlines and treated COVID-19 patients [11,12].

In a recent cross-sectional study, Bauernfeind et al., 2021 investigated the opinions of the healthcare workers in Germany about COVID-19 vaccination [13]. This study revealed that 59.5% of the surveyed subjects were willing to get vaccinated, 21.4% were hesitant, and 18.7% were against getting vaccinated, thus boldlying the need for innovative strategies to tackle vaccine hesitancy and resistance drivers among German healthcare workers [13]. Aversion to side effects had been widely recognized as one of the key drivers of vaccine hesitancy that requires transparent and independent safety evidence of the vaccines, especially the novel ones [14].
The overarching aim of this study was to investigate the short-term side effects following COVID-19 vaccines reported by German healthcare workers. The primary objective was to estimate the prevalence of the side effects of both mRNA-based and viral vector-based vaccines. The secondary objectives were (a) to evaluate the demographic and medical risk factors of the COVID-19 vaccines side effects; and (b) to compare between the side effects frequency and intensity of mRNA-based versus viral vector-based vaccines.

2. Materials and Methods

2.1. Design

A cross-sectional survey-based study had been designed as a post-marketing (phase IV) trial between February and April 2021 to evaluate the self-reported side effects of COVID-19 vaccines among healthcare workers in the Federal Republic of Germany. The study utilized a self-administered questionnaire (SAQ) developed and delivered online through KoboToolbox (Harvard Humanitarian Initiative, Cambridge, MA, USA) for data collection [15]. The study protocol was registered a priori at the U.S. National Library of Medicine (NLM) under the identifier NCT04706156 [16,17]. The study was entirely conducted and reported according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cross-sectional studies [18].

2.2. Participants

The eligible participants of this study were healthcare workers who had been vaccinated among the priority groups recommended by the Standing Committee on Vaccination (STIKO) of Robert Koch Institute (Berlin, Germany) during the first quarter of 2021 [11]. The healthcare workers who received the Pfizer-BioNTech vaccine (BTN162 vaccine), Moderna vaccine (mRNA-1273 vaccine), and the AstraZeneca-Oxford vaccine (ChAdOx1 COVID-19 vaccine) were included in this study regardless of the number of doses they had received by the time of filling the questionnaire. While the Janssen vaccine (Ad26.COV2.S vaccine) was authorized by the EMA since 11 March 2021 it was not yet deployed on large scale among the German population when the study was carried out, and it was not even offered to the priority group of healthcare workers. Therefore, we used the AstraZeneca-Oxford vaccine as a representative for the viral vector technology.

A non-random sampling technique was used in recruiting the participants, as printed posters within the vaccination center (Kiel, Schleswig-Holstein, Germany) were used to promote the study among the target participants. Additionally, a snow-balling technique was used to invite participants from other recruitment locations (Bayern, Bavaria, Germany) and (Giessen, Hessen, Germany).

Participation in this study was entirely voluntary, and the participants received no financial compensation in order to minimize the risks of response bias and performance bias. The participants were allowed to withdraw from the study at any moment until data submission without the need to justify their decision.

The sample size was calculated using Epi Info™ version 7.2.4 (CDC. Atlanta, GA. 2020). The formula of population survey studies was used to achieve 5% of error margin and 95% confidence level [19]. The expected frequency (outcome probability) is assumed to be 60% as the prevalence of side effects following COVID-19 vaccines ranged between 62% to 93% in our previous studies [20–22] (Figure 1).
Population size: total number of healthcare workers in Germany in 2018.

Expected frequency: the overall prevalence of side effects following COVID-19 vaccines ranged between 62% and 93%; therefore, 60% was assumed as a threshold.

Acceptable Margin of Error: 5% will be the permissible level for all CoVaST groups.

Design effect: 1—per the recommendation of the CDC for simple sampling.

Clusters: 1—per the recommendation of the CDC for simple sampling.

The sample size is 369 (CI 95%).

Figure 1. Sample size of healthcare workers (HCWs) in Germany—Epi-Info™ version 7.2.4. [19,23].

2.3. Instrument

The SAQ used in this study consisted of 28 multiple-choice items, which were adapted from the safety reports of phase III trials published by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) for the mRNA-based vaccines, and the European Medicines Agency (EMA, Amsterdam, The Netherlands) for the viral vector-based vaccine [24–26].

The validation and reliability testing process was described in detail previously elsewhere [20]. The content validity was assessed by an experts’ panel, and the test re-test reliability of the suggested SAQ yielded a mean Cohen’s kappa coefficient of 0.89 ± 0.13 (0.54–1), thus indicating substantial reliability [20].

The items of the SAQ were stratified into four main categories: (a) demographic information including gender, age, profession, work experience, and federal state; (b) medical anamneses including chronic disease and medical treatments; (c) COVID-19-related anamnesis including previous infection, exposure, type of vaccine, number of doses; and (d) the local, systemic, oral, and skin-related side effects of COVID-19 vaccines [20–22].

2.4. Ethics

The study was fully reviewed and approved by the Ethics Committee of the Faculty of Medicine at the Justus Liebig University of Giessen (Ref. 55/20). The study data was controlled and processed by Masaryk University (MUNI) in full compliance with the General Data Protection Regulation (GDPR) [27]. A digital informed consent was obtained from each participant before participation in the study, and no identifying personal information was collected that may facilitate the retrospective identification of the participants.

2.5. Analysis

All statistical tests were executed by the Statistical Package for the Social Sciences (SPSS) version 27.0 (SPSS Inc., Chicago, IL, USA, 2020) [28]. The normality of data was evaluated using the Shapiro–Wilk test with a significance level (Sig.) of 0.05. Primarily, descriptive statistics was used to present and summarize the categorical variables like gender, profession, work experience, region, medical anamneses, COVID-19-related anamneses, and individual side effects by frequency (n) and percentage (%). The continuous variables were age, number of chronic illnesses and medical treatments, and number of side effects either locally, systemically, orally, or dermatologically by mean (μ) and standard deviation (SD).

Chi-squared test ($\chi^2$), Fisher’s exact test, Mann–Whitney (U) test, Kruskal–Wallis (H) test were used to estimate the association between demographic and medical risk factors of COVID-19 vaccines and evaluate the differences between mRNA-based and viral
vector-based COVID-19 vaccines. Binary logistic regression for the side effects occurrence either locally, systemically, or generally was used to evaluate the proposed demographic and medical risk factors. All inferential tests were carried out assuming a confidence level (CI) of 95% and a significance value of 0.05.

3. Results
3.1. Demographic Characteristics

A total of 599 participants completed the SAQ properly; therefore, they were included in the final analysis. While 386 participants received Pfizer-BioNTech and 88 received Moderna (mRNA-based vaccine; \( n = 474 \)), 125 received AstraZeneca-Oxford (viral vector-based vaccine; \( n = 125 \)). The included participants received their first dose of the vaccines between 27 December 2020 and 30 March 2021.

The optimal sample size was reached for the total number of participants and for participants with Pfizer-BioNTech vaccine. The median age of the participants was 39 years old; therefore, it was used in the downstream analyses as a cut-off for age-dependent comparisons. Out of the 474 mRNA-based vaccine recipients, 73.6% were females, 50.4% were \( \leq 39 \) years-old, 51.3% were nurses, 40.9% had \( > 20 \) years of work experience, and 75.7% were from Schleswig-Holstein. Out of the 125 viral vector-based vaccine recipients, 67.2% were females, 50.4% were \( \leq 39 \) years-old, 40.8% were nurses, 37.6% had 1–5 years of work experience, and 70.4% were from Schleswig-Holstein (Table 1).

Table 1. Demographic Characteristics of Participating German Healthcare Workers, February–March 2021 (\( n = 599 \)).

| Variable | Outcome | mRNA Vaccine | Viral Vector Vaccine | Total |
|----------|---------|--------------|----------------------|-------|
| Gender   | Female  | 349 (73.6%)  | 84 (67.2%)           | 433 (72.3%) |
|          | Male    | 122 (25.7%)  | 41 (32.8%)           | 163 (27.2%) |
|          | Non-binary | 2 (0.4%) | 0 (0%)              | 2 (0.3%)   |
|          | Prefer not to say | 1 (0.2%) | 0 (0%)             | 1 (0.2%)   |
| Age      | \( \leq 39 \) years-old | 239 (50.4%) | 63 (50.4%) | 302 (50.4%) |
|          | \( > 39 \) years-old | 235 (49.6%) | 62 (49.6%) | 297 (49.6%) |
| Profession | Physician | 60 (12.7%) | 35 (28%) | 95 (15.9%) |
|          | Dentist | 62 (13.1%) | 20 (16%) | 82 (13.7%) |
|          | Nurse  | 243 (51.3%) | 51 (40.8%) | 294 (49.1%) |
|          | Pharmacist | 4 (0.8%) | 3 (2.4%) | 7 (1.2%) |
|          | Lab Worker | 16 (3.4%) | 2 (1.6%) | 18 (3%) |
|          | Psychologist | 15 (3.2%) | 0 (0%) | 15 (2.5%) |
|          | Dietitian | 3 (0.6%) | 2 (1.6%) | 5 (0.8%) |
|          | Physiotherapist | 8 (1.7%) | 0 (0%) | 8 (1.3%) |
|          | Paramedic | 7 (1.5%) | 8 (6.4%) | 15 (2.5%) |
|          | Midwife | 3 (0.6%) | 0 (0%) | 3 (0.5%) |
|          | Other | 53 (11.2%) | 4 (3.2%) | 57 (9.5%) |
| Work Experience | 1–5 years | 146 (30.8%) | 47 (37.6%) | 193 (32.2%) |
|          | 6–10 years | 55 (11.6%) | 16 (12.8%) | 71 (11.9%) |
|          | 11–20 years | 79 (16.7%) | 20 (16%) | 99 (16.5%) |
|          | \( > 20 \) years | 194 (40.9%) | 42 (33.6%) | 236 (39.4%) |
| State    | Schleswig-Holstein | 359 (75.7%) | 88 (70.4%) | 447 (74.6%) |
|          | Bavaria | 77 (16.2%) | 23 (18.4%) | 100 (16.7%) |
|          | Hessen | 27 (5.7%) | 13 (10.4%) | 40 (6.7%) |
|          | Nordrhein-Westfalen | 4 (0.8%) | 1 (0.8%) | 5 (0.8%) |
|          | Berlin | 2 (0.4%) | 0 (0%) | 2 (0.3%) |
|          | Other | 5 (1.1%) | 0 (0%) | 5 (0.8%) |

3.2. Medical Anamneses

Overall, 29.5% and 24.8% of mRNA-based vaccine and viral vector-based vaccine recipients reported at least one non-communicable disease, respectively. The most common chronic illness among mRNA-based vaccine recipients was thyroid disease (7.6%), followed
by chronic hypertension (6.1%), and asthma (6.1%). Similarly, thyroid disease (8.8%) was the most common illness among viral vector-based vaccine recipients, followed by chronic hypertension (5.6%). The only significant difference between mRNA-based vaccine recipients and viral vector-based vaccine recipients ($\chi^2 = 4.115$ and 7.146; $\text{Sig.} = 0.043$ and 0.030) was in terms of asthma (6.1% vs. 1.6%) and chronic obstructive pulmonary disease (0.2% vs. 2.4%).

While 35.4% of mRNA-based vaccine recipients were taking medications regularly, only 24% of viral vector-based vaccine recipients were taking them ($\chi^2 = 5.853$; $\text{Sig.} = 0.016$). Antihypertensive drugs (12.9%) were the most common among mRNA-based vaccine recipients, followed by thyroid hormone supplements (8.9%), contraceptives (5.3%), immunosuppressive drugs (3.8%), and antidepressants (3.6%). In the viral vector-based vaccine group, thyroid hormone supplements (8.8%) were the most common medication, followed by antihypertensive drugs (5.6%), antidepressants (5.6%), antidepressants (5.6%), and contraceptives (3.2%) (Table 2).

Table 2. Medical Anamneses of Participating German Healthcare Workers, February–March 2021 ($n = 599$).

| Variable                        | Outcome | mRNA Vaccine | Viral Vector Vaccine | Total | Sig. |
|--------------------------------|---------|--------------|---------------------|-------|------|
| Noncommunicable Diseases (NCDs) | Dermatologic Disorder | 5 (1.1%) | 1 (0.8%) | 6 (1%) | 1.000 * |
|                                | Diabetes Mellitus | 9 (1.9%) | 0 (0%) | 9 (1.5%) | 0.216 * |
|                                | Hepatic Disease | 2 (0.4%) | 0 (0%) | 2 (0.3%) | 1.000 * |
|                                | Neurologic Disorder | 6 (1.3%) | 3 (2.4%) | 9 (1.5%) | 0.404 * |
|                                | Ophthalmic Disease | 1 (0.2%) | 0 (0%) | 1 (0.2%) | 1.000 * |
|                                | Otolaryngologic Disease | 1 (0.2%) | 0 (0%) | 1 (0.2%) | 1.000 * |
|                                | Renal Disease | 0 (0%) | 1 (0.8%) | 1 (0.2%) | 0.209 * |
|                                | Rheumatoid Arthritis | 13 (2.7%) | 3 (2.4%) | 16 (2.7%) | 1.000 * |
|                                | Thyroid Disease | 36 (7.6%) | 11 (8.8%) | 47 (7.8%) | 0.656 |
| Intensity ($\mu \pm \text{SD}$) | 0.30 ± 0.46 | 0.25 ± 0.43 | 0.29 ± 0.54 | 0.354 |
| Total                          | 140 (29.5%) | 31 (24.8%) | 171 (28.5%) | 0.30 |

| Medications                     | Outcome | mRNA Vaccine | Viral Vector Vaccine | Total | Sig. |
|--------------------------------|---------|--------------|---------------------|-------|------|
| Antihypertensive                | 61 (12.9%) | 7 (5.6%) | 68 (11.4%) | 0.023 |
| Cholesterol-lowering            | 3 (0.6%) | 0 (0%) | 3 (0.5%) | 1.000 * |
| Contraceptives                  | 25 (5.3%) | 4 (3.2%) | 29 (4.8%) | 0.336 |
| Eye Drops                       | 1 (0.2%) | 0 (0%) | 1 (0.2%) | 1.000 * |
| Immunosuppressives              | 18 (3.8%) | 2 (1.6%) | 20 (3.3%) | 0.277 * |
| Narcotic Analgesics             | 1 (0.2%) | 3 (2.4%) | 4 (0.7%) | 0.030 * |
| Thyroid Hormone                 | 42 (8.9%) | 11 (8.8%) | 53 (8.8%) | 0.983 |
| Intensity ($\mu \pm \text{SD}$) | 0.42 ± 0.63 | 0.32 ± 0.63 | 0.40 ± 0.63 | 0.031 |
| Total                          | 168 (35.4%) | 30 (24%) | 198 (33.1%) | 0.016 |

Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.
3.3. COVID-19-Related Anamneses

However, the vast majority of mRNA-based vaccine group (90.3%) received two doses, the vast majority of viral vector-based vaccine group (99.2%) received only one dose by the time they filled in the SAQ ($\chi^2 = 389.771; \text{Sig.} < 0.001$). Only four recipients of mRNA vaccine and two recipients of viral vector-based vaccine were previously infected by SARS-CoV-2. In total, 175 (29.2%) participants reported being exposed to COVID-19 patients during the last months (Table 3).

Table 3. COVID-19-related Anamneses of Participating German Healthcare Workers, February–March 2021 ($n = 599$).

| Variable | Outcome | mRNA Vaccine | Viral Vector Vaccine | Total | Sig. |
|----------|---------|--------------|----------------------|-------|------|
| Doses    | One     | 46 (9.7%)    | 124 (99.2%)          | 170 (28.4%) | <0.001 |
|          | Two     | 428 (90.3%)  | 1 (0.8%)             | 429 (71.6%) |     |
| Infection| Yes     | 4 (0.8%)     | 2 (1.6%)             | 6 (1%)  | 0.610 * |
| Exposure | Yes     | 143 (30.2%)  | 32 (25.6%)           | 175 (29.2%) | 0.318 |

Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.

3.4. Local and Systemic Side Effects

All local side effects, related to the injection site, were more prevalent in the mRNA-based vaccine group than the viral vector-based vaccine group. A total of 78.3% and 70.4% of mRNA-based vaccine and viral vector-based vaccine recipients reported at least one local side effect ($\chi^2 = 3.421; \text{Sig.} = 0.064$), respectively. Overall, injection site pain (75.6%) was the most prevalent local side effect, followed by injection site swelling (18%) and injection site redness (10.4%). Injection site pain (77.4% vs. 68.8%, respectively) was significantly more common in the mRNA-based vaccine group compared to the viral vector-based vaccine group ($\chi^2 = 3.993; \text{Sig.} = 0.046$).

On the contrary, all systemic side effects were more prevalent in the viral vector-based vaccine group than the mRNA-based vaccine group. A total of 87.2% and 61% of viral vector-based vaccine and mRNA-based vaccine recipients reported at least one systemic side effect ($\chi^2 = 30.522; \text{Sig.} < 0.001$), respectively. Overall, the most common systemic side effect was headache/fatigue (53.6%), followed by muscle pain (33.2%), malaise (25%), chills (23%), and joint pain (21.2%). The differences between the viral vector-based vaccine group and mRNA-based vaccine group were statistically significant ($\chi^2 = 97.782, 106.419, 27.506, 27.292, 63.907, 16.161 and 47.501; \text{Sig.} < 0.001, < 0.001, < 0.001, < 0.001, < 0.001, < 0.001$ and < 0.001, respectively) in terms of fever (48% vs. 9.9%), chills (57.6% vs. 13.9%), headache/fatigue (74.4% vs. 48.1%), muscle pain (52.8% vs. 28.1%), joint pain (47.2% vs. 14.3%), nausea (20.8% vs. 8.2%), and malaise (48.8% vs. 18.8%).

In general, 86.3% and 80% of the side effects reported by mRNA-based vaccine and viral vector-based recipients remained 1–3 days. The severe side effects that required medical attention were reported only by two (0.4%) mRNA-based vaccine recipients and four (3.2%) viral vector-based vaccine recipients (Sig. = 0.019; 2-S Fisher’s exact test) (Table 4).

3.5. Oral and Skin-Related Side Effects

A total of 106 (17.7%) participants reported experiencing at least one oral side effect, with 12.4% and 37.6% of mRNA-based vaccine and viral vector-based vaccine recipients being affected ($\chi^2 = 42.967; \text{Sig.} < 0.001$), respectively.

The most prevalent oral side effect was vesicles (6.3%), followed by bleeding gingiva (4.3%), halitosis (3.7%), oral paranesthesia (2.2%), swollen mucosa (2.2%), and ulcers (2%). Taste disturbance (6.4% vs. 0.8%), vesicles (12.8% vs. 4.6%), halitosis (10.4% vs. 1.9%), bleeding gingiva (12% vs. 2.3%), and xerostomia (2.4% vs. 0%) were significantly more common among viral vector-based vaccine recipients.
Table 4. COVID-19 Vaccines General Side Effects of Participating German Healthcare Workers, February–March 2021 (n = 599).

| Variable          | Outcome                  | mRNA Vaccine | Viral Vector Vaccine | Total       | Sig.     |
|-------------------|--------------------------|--------------|----------------------|-------------|----------|
|                   |                          |              |                      |             |          |
| **Local SE**      | Injection Site Pain      | 367 (77.4%)  | 86 (68.8%)           | 453 (75.6%) | 0.046    |
|                   | Injection Site Swelling  | 88 (18.6%)   | 20 (16%)             | 108 (18%)   | 0.507    |
|                   | Injection Site Redness   | 51 (10.8%)   | 11 (8.8%)            | 62 (10.4%)  | 0.522    |
|                   | Intensity (µ ± SD)       | 1.07 ± 0.80  | 0.94 ± 0.81          | 1.04 ± 0.81 | 0.069    |
|                   | Total                    | 371 (78.3%)  | 88 (70.4%)           | 459 (76.6%) | 0.064    |
| **Systemic SE**   | Fever                    | 47 (9.9%)    | 60 (48%)             | 107 (17.9%) | <0.001   |
|                   | Chills                   | 66 (13.9%)   | 72 (57.6%)           | 138 (23%)   | <0.001   |
|                   | Headache/Fatigue         | 228 (48.1%)  | 93 (74.4%)           | 321 (53.6%) | <0.001   |
|                   | Muscle Pain              | 133 (28.1%)  | 66 (52.8%)           | 199 (33.2%) | <0.001   |
|                   | Joint Pain               | 68 (14.3%)   | 59 (47.2%)           | 127 (21.2%) | <0.001   |
|                   | Nausea                   | 39 (8.2%)    | 26 (20.8%)           | 65 (10.9%)  | <0.001   |
|                   | Malaise                  | 89 (18.8%)   | 61 (48.8%)           | 150 (25%)   | <0.001   |
|                   | Lymphadenopathy          | 43 (9.1%)    | 13 (10.4%)           | 56 (9.3%)   | 0.650    |
|                   | Intensity (µ ± SD)       | 1.50 ± 1.75  | 3.60 ± 2.25          | 1.94 ± 2.05 | <0.001   |
|                   | Total                    | 289 (61%)    | 109 (87.2%)          | 398 (66.4%) | <0.001   |
| **General SE**    | 1 Day                    | 161 (39.6%)  | 51 (44.3%)           | 212 (40.6%) | 0.155    |
|                   | 3 Days                   | 190 (46.7%)  | 41 (35.7%)           | 231 (44.3%) | 0.137    |
|                   | 5 Days                   | 22 (5.4%)    | 6 (5.2%)             | 28 (5.4%)   | 0.940    |
|                   | 1 Week                   | 21 (5.2%)    | 5 (4.3%)             | 26 (5%)     | 0.834    |
|                   | >1 Week                  | 12 (2.9%)    | 12 (10.4%)           | 24 (4.6%)   | 0.001    |
|                   | >1 Month                 | 1 (0.2%)     | 0 (0%)               | 1 (0.2%)    | 1.000 *  |
|                   | Intensity (µ ± SD)       | 2.57 ± 2.16  | 4.54 ± 2.75          | 2.98 ± 2.43 | <0.001   |
|                   | Total                    | 413 (87.1%)  | 115 (92%)            | 528 (88.1%) | 0.134    |
| **Severe SE**     | Total                    | 2 (0.4%)     | 4 (3.2%)             | 6 (1%)      | 0.019 *  |

Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.

More than three-fourths (75.6%) of oral side effects emerged within the first week after vaccination. The most common site for ulcers, vesicles and blisters were labial/buccal mucosa (43.2%), followed by lips (29.5%) and tongue (27.3%). Tongue (57.1%) and labial/buccal mucosa (57.1%) were the common sites for white/red plaque (Table 5).

A total of 21 (3.5%) participants reported experiencing at least one skin-related side effect, with 3% and 5.6% of mRNA-based vaccine and viral vector-based vaccine recipients being affected (Sig. = 0.171; 2-S Fisher’s exact test), respectively.

The most prevalent skin-related side effect was rash (2.8%), followed by urticaria (0.7%), and angioedema (0.7%). The most common affected sites were face (57.1%), followed by upper limb (38.1%), and lower limb (19%) (Table 6).

3.6. COVID-19 Vaccines Side Effects by Gender

The local side effects were almost equally distributed between female (78.2%) and male (77.9%) participants who received mRNA-based vaccines. On the other hand, the females who received the viral vector-based vaccine had a significantly higher prevalence of local side effects (χ² = 5.989; Sig. = 0.014) compared to their male counterparts, 77.4% vs. 56.1, respectively.

Similarly, the difference between female and male participants in terms of systemic side effects was not statistically significant in the case of mRNA-based vaccines (χ² = 1.868; Sig. = 0.172), but it was statistically significant in the case of the viral vector-based vaccine (χ² = 4.578; Sig. = 0.032).

In the mRNA-based vaccine group, females had higher prevalence of fever (10.6% vs. 7.4%), chills (14.9% vs. 11.5), headache/fatigue (51.3% vs. 38.5%), muscle pain (28.4% vs. 22.5%), nausea (9.9% vs. 5.5%), and vomiting (1.8% vs. 0.5%), whereas males had higher prevalence of headache/fatigue (54.1% vs. 48.6%), muscle pain (37.7% vs. 29.1%), nausea (7.6% vs. 4.8%), vomiting (1.7% vs. 0.3%), and joint pain (6.5% vs. 3.1%).
vs. 27%), joint pain (15.8% vs. 9.8%), and lymphadenopathy (10.3% vs. 4.9%) than males (Figure 2).

Table 5. COVID-19 Vaccines Oral Side Effects of Participating German Healthcare Workers, February–March 2021 (n = 599).

| Variable                      | Outcome                | mRNA Vaccine | Viral Vector Vaccine | Total   | Sig.   |
|-------------------------------|------------------------|--------------|----------------------|---------|--------|
| Oral SE Ulcers                | 8 (1.7%)               | 4 (3.2%)     | 12 (2%)              | 0.286 * |
| Vesicles                      | 22 (4.6%)              | 16 (12.8%)   | 38 (6.3%)            | 0.001 * |
| Blisters                      | 1 (0.2%)               | 1 (0.8%)     | 2 (0.3%)             | 0.374 * |
| Angular Cheilitis             | 2 (0.4%)               | 1 (0.8%)     | 3 (0.5%)             | 0.505 * |
| White/Red Plaque              | 3 (0.6%)               | 4 (3.2%)     | 7 (1.2%)             | 0.038 * |
| Oral Paraesthesia             | 11 (2.3%)              | 2 (1.6%)     | 13 (2.2%)            | 1.000   |
| Taste Disturbance             | 4 (0.8%)               | 8 (6.4%)     | 12 (2%)              | 0.001   |
| Xerostomia                    | 0 (0%)                 | 3 (2.4%)     | 3 (0.5%)             | 0.009   |
| Halitosis                     | 9 (1.9%)               | 13 (10.4%)   | 22 (3.7%)            | <0.001  |
| Bleeding Gingiva              | 11 (2.3%)              | 15 (12%)     | 26 (4.3%)            | <0.001  |
| Swollen Mucosa                | 8 (1.7%)               | 5 (4%)       | 13 (2.2%)            | 0.158   |

| Oral SE Onset                  |                        |              |                     |         |
| Total                          | 59 (12.4%)             | 47 (37.6%)   | 106 (17.7%)         | <0.001  |

| Ulcers/Vesicles/Blisters Location | Tongue | 5 (18.5%) | 7 (41.2%) | 12 (27.3%) | 0.164 * |
|                                  | Palate  | 8 (29.6%) | 3 (17.6%) | 11 (25%)   | 0.486   |
|                                  | Labial/Buccal | 10 (37%) | 9 (52.9%) | 19 (43.2%) | 0.300   |
|                                  | Mucosa  | 2 (7.4%)  | 1 (5.9%)  | 3 (6.8%)   | 1.004   |
|                                  | Gingiva | 9 (33.3%) | 4 (23.5%) | 13 (29.5%) | 0.488   |

| White/Red Plaque Location       | Tongue Dorsum | 1 (33.3%) | 3 (75%)  | 4 (57.1%)  | 0.486   |
|                                  | Soft Palate   | 1 (33.3%) | 2 (50%)  | 3 (42.9%)  | 1.000   |
|                                  | Labial/Buccal | 2 (66.7%) | 2 (50%)  | 4 (57.1%)  | 1.000   |

Chi-squared test and Fisher’s exact test (*) were used with a significance level of <0.05.

Table 6. COVID-19 Vaccines Skin-related Side Effects of Participating German Healthcare Workers, February–March 2021 (n = 599).

| Variable                      | Outcome                | mRNA Vaccine | Viral Vector Vaccine | Total   | Sig.   |
|-------------------------------|------------------------|--------------|----------------------|---------|--------|
| Skin-related SE Rash          | 12 (2.5%)              | 5 (4%)       | 17 (2.8%)            | 0.369   |
| Urticaria                     | 2 (0.4%)               | 2 (1.6%)     | 4 (0.7%)             | 0.194   |
| Angioedema                    | 2 (0.4%)               | 2 (1.6%)     | 4 (0.7%)             | 0.194   |

| Skin-related SE Location      | Total                  | 14 (3%)      | 7 (5.6%)             | 21 (3.5%) | 0.171 * |

| Skin-related SE Location      | Face                   | 8 (57.1%)    | 4 (57.1%)            | 12 (57.1%) | 1.000 * |
| Upper Limb                    | 6 (42.9%)              | 2 (28.6%)    | 8 (38.1%)            | 0.656     |
| Lower Limb                    | 3 (21.4%)              | 1 (14.3%)    | 4 (19%)              | 1.000     |
| Trunk                         | 0 (0%)                 | 2 (28.6%)    | 2 (9.5%)             | 0.100     |
| Back                          | 1 (7.1%)               | 1 (14.3%)    | 2 (9.5%)             | 1.000     |

Chi-squared test and Fisher’s exact test (*) were used with a significance level of <0.05.
3.6. COVID-19 Vaccines Side Effects by Gender

The local side effects were almost equally distributed between female (78.2%) and male (77.9%) participants who received mRNA-based vaccines. On the other hand, the females who received the viral vector-based vaccine had a significantly higher prevalence (\(\chi^2 = 5.989; \text{Sig.} = 0.014\)) compared to their male counterparts, 77.4% vs. 56.1, respectively.

Similarly, the difference between female and male participants in terms of systemic side effects was not statistically significant in the case of mRNA-based vaccines (\(\chi^2 = 1.868; \text{Sig.} = 0.172\)), but it was statistically significant in the case of the viral vector-based vaccine (\(\chi^2 = 4.578; \text{Sig.} = 0.032\)).

In the mRNA-based vaccine group, females had higher prevalence of fever (10.6% vs. 7.4%), chills (14.9% vs. 11.5), headache/fatigue (51.3% vs. 38.5%), muscle pain (28.4% vs. 27%), joint pain (15.8% vs. 9.8%), and lymphadenopathy (10.3% vs. 4.9%) than males (Figure 2).

In the viral vector-based vaccine group, females had higher prevalence of fever (53.6% vs. 36.6%), chills (60.7% vs. 51.2%), headache/fatigue (81% vs. 61%), muscle pain (56% vs. 46.3%), joint pain (52.4% vs. 36.6%), nausea (22.6% vs. 17.1%), and malaise (51.2% vs. 43.9%) (Figure 3).

In the viral vector-based vaccine group, females had higher prevalence of fever (53.6% vs. 36.6%), chills (60.7% vs. 51.2%), headache/fatigue (81% vs. 61%), muscle pain (56% vs. 46.3%), joint pain (52.4% vs. 36.6%), nausea (22.6% vs. 17.1%), and malaise (51.2% vs. 43.9%) (Figure 3).

### Table 7.
COVID-19 Vaccines Side Effects of Participating German Healthcare Workers Stratified by Gender, February–March 2021 (n = 596).

| Variable          | Outcome | mRNA-Based Vaccine | Viral Vector Vaccine | Sig. | Female | Male | Sig. |
|-------------------|---------|--------------------|----------------------|------|--------|------|------|
| Local SE          | Injection Site Pain | 272 (77.9%) | 93 (76.2%) | 0.697 | 63 (75%) | 23 (56.1%) | 0.032 |
|                   | Injection Site Swelling | 61 (17.5%) | 25 (20.5%) | 0.458 | 15 (17.9%) | 5 (12.2%) | 0.418 |
|                   | Injection Site Redness | 35 (10%) | 15 (12.3%) | 0.484 | 7 (8.3%) | 4 (9.8%) | 0.792 |
|                   | Intensity (\(\mu\) ± SD) | 1.05 ± 0.80 | 1.09 ± 0.83 | 0.715 | 1.01 ± 0.75 | 0.78 ± 0.91 | 0.033 |
|                   | Total | 273 (78.2%) | 95 (77.9%) | 0.935 | 65 (77.4%) | 23 (56.1%) | 0.014 |
| Systemic SE       | Fever | 37 (10.6%) | 9 (7.4%) | 0.302 | 45 (53.6%) | 15 (36.6%) | 0.074 |
|                   | Chills | 52 (14.9%) | 14 (11.5%) | 0.348 | 51 (60.7%) | 21 (51.2%) | 0.313 |
|                   | Headache/Fatigue | 179 (51.3%) | 47 (38.5%) | 0.015 | 68 (81%) | 25 (61%) | 0.016 |
|                   | Muscle Pain | 99 (28.4%) | 33 (27%) | 0.780 | 47 (56%) | 19 (46.3%) | 0.312 |
|                   | Joint Pain | 55 (15.8%) | 12 (9.8%) | 0.107 | 44 (52.4%) | 15 (36.6%) | 0.097 |
|                   | Nausea | 28 (8%) | 10 (8.2%) | 0.952 | 19 (22.6%) | 7 (17.1%) | 0.473 |
|                   | Malaise | 64 (18.3%) | 24 (19.7%) | 0.745 | 43 (51.2%) | 18 (43.9%) | 0.444 |
|                   | Lymphadenopathy | 36 (10.3%) | 6 (4.9%) | 0.072 | 7 (8.3%) | 6 (14.6%) | 0.351 |
|                   | Intensity (\(\mu\) ± SD) | 1.58 ± 1.81 | 1.27 ± 1.56 | 0.142 | 3.86 ± 2.14 | 3.07 ± 2.41 | 0.079 |
|                   | Total | 219 (62.8%) | 68 (55.7%) | 0.172 | 77 (91.7%) | 32 (78%) | 0.032 |

**Figure 2.** Side Effects of mRNA-based COVID-19 Vaccines Reported by German Healthcare Workers Stratified by Gender, February–March 2021 (n = 474).

**Figure 3.** Side Effects of Viral Vector-based COVID-19 Vaccines Reported by German Healthcare Workers Stratified by Gender, February–March 2021 (n = 125).
The severe side effects were exclusively reported by females (n = 2) in the mRNA-based vaccine, and in the viral vector-based vaccine, the female:male ratio was 3:1. Oral side effects affected males slightly more than females in the mRNA-based vaccine group (14.8% vs. 11.7%) and the viral vector-based vaccine group (39% vs. 36.9%). In the mRNA-based vaccine group, all the skin-related side effects were reported by females (Table 7).

### Table 7. COVID-19 Vaccines Side Effects of Participating German Healthcare Workers Stratified by Gender, February–March 2021 (n = 596).

| Variable | Outcome | mRNA-Based Vaccine | Viral Vector Vaccine |
|----------|---------|---------------------|----------------------|
| Local SE | Injection Site Pain | 272 (77.9%) | 93 (76.2%) | 0.697 | 63 (75%) | 23 (56.1%) | 0.032 |
|          | Injection Site Swelling | 61 (17.5%) | 25 (20.5%) | 0.458 | 15 (17.9%) | 5 (12.2%) | 0.418 |
|          | Injection Site Redness | 35 (10%) | 15 (12.3%) | 0.484 | 7 (8.3%) | 4 (9.8%) | 0.792 |
| Intensity (µ ± SD) | | 1.05 ± 0.80 | 1.09 ± 0.83 | 0.715 | 1.01 ± 0.75 | 0.78 ± 0.91 | 0.033 |
| Total    | | 273 (78.2%) | 95 (77.9%) | 0.935 | 65 (77.4%) | 23 (56.1%) | 0.014 |
| Systemic SE | Fever | 37 (10.6%) | 9 (7.4%) | 0.302 | 45 (53.6%) | 15 (36.6%) | 0.074 |
|          | Chills | 52 (14.9%) | 14 (11.5%) | 0.348 | 51 (60.7%) | 21 (51.2%) | 0.313 |
|          | Headache/Fatigue | 179 (51.3%) | 47 (38.5%) | 0.015 | 68 (81%) | 25 (61%) | 0.016 |
|          | Muscle Pain | 99 (28.4%) | 33 (27%) | 0.780 | 47 (56%) | 19 (46.3%) | 0.312 |
|          | Joint Pain | 55 (15.8%) | 12 (9.8%) | 0.107 | 44 (52.4%) | 15 (36.6%) | 0.097 |
|          | Nausea | 28 (8%) | 10 (8.2%) | 0.952 | 19 (22.6%) | 7 (17.1%) | 0.473 |
|          | Malaise | 64 (18.3%) | 24 (19.7%) | 0.745 | 43 (51.2%) | 18 (43.9%) | 0.444 |
|          | Lymphadenopathy | 36 (10.3%) | 6 (4.9%) | 0.072 | 7 (8.3%) | 6 (14.6%) | 0.351 * |
| Intensity (µ ± SD) | | 1.58 ± 1.81 | 1.27 ± 1.56 | 0.142 | 3.86 ± 2.14 | 3.07 ± 2.41 | 0.079 |
| Total    | | 219 (62.8%) | 68 (55.7%) | 0.172 | 77 (91.7%) | 32 (78%) | 0.032 |
| Severe SE | Total | 2 (0.6%) | 0 (0%) | 1.000 * | 3 (3.6%) | 1 (2.4%) | 1.000 * |
| Oral SE | Total | 41 (11.7%) | 18 (14.8%) | 0.388 | 31 (36.9%) | 16 (39%) | 0.818 |
| Skin-related SE | Total | 13 (3.7%) | 0 (0%) | 0.129 | 5 (6%) | 2 (4.9%) | 1.000 * |

Chi-squared test, Fisher’s exact test (*) and Mann–Whitney test were used with a significance level of <0.05.

3.7. COVID-19 Vaccines Side Effects by Age

The local side effects were almost equally distributed between the younger age group (≤ 39 years-old) and the older age group (≤ 39 years-old) participants who received mRNA-based vaccines (78.7% vs. 77.9%, respectively) and the viral vector-based vaccine (73% vs. 67.7%, respectively).

The difference between the younger age group and older age group participants in terms of systemic side effects was statistically significant in case of mRNA-based vaccines ($\chi^2 = 8.281; \text{Sig.} = 0.004$), but it was not statistically significant in case of the viral vector-based vaccine ($\chi^2 = 1.075; \text{Sig.} = 0.300$). While the younger age group was more affected by systemic side effects following mRNA-based vaccines (67.4% vs. 54.5%), they were less affected by systemic side effects following viral vector-based vaccine (84.1% vs. 90.3%) compared to the older age group.

In the mRNA-based vaccine group, the younger age group had a significantly higher level of headache/fatigue ($\chi^2 = 11; \text{Sig.} = 0.001$) and joint pain ($\chi^2 = 7.882; \text{Sig.} = 0.005$) than the older age group (Figure 4).
Figure 4. Side Effects of mRNA-based COVID-19 Vaccines Reported by German Healthcare Workers Stratified by Age Group, February–March 2021 (n = 474).

In the viral vector-based vaccine group, the older age group had a higher prevalence of most of the investigated systemic side effects but without statistical significance. The largest difference between the age groups was in the case of chills (10.5%), followed by fever (10.3%), and joint pain (8.7%) (Figure 5).

Figure 5. Side Effects of Viral Vector COVID-19 Vaccines Reported by German Healthcare Workers Stratified by Age Group, February–March 2021 (n = 125).
The severe side effects were exclusively reported by the younger age group (\(n = 2\)) in the mRNA-based vaccine, and in the viral vector-based vaccine, the older age group:younger age group ratio was 3:1. Oral side effects affected the younger age group slightly more than the older age group in the mRNA-based vaccine group (13.8% vs. 11.1%) and the viral vector-based vaccine group (41.3% vs. 33.9%) (Table 8).

**Table 8.** COVID-19 Vaccines Side Effects of Participating German Healthcare Workers Stratified by Age, February–March 2021 (\(n = 599\)).

| Variable         | Outcome                  | mRNA-Based Vaccine | Viral Vector Vaccine |
|------------------|--------------------------|--------------------|----------------------|
|                  | \(\leq 39\) Years-Old   | \(>39\) Years-Old | Sig.         | \(\leq 39\) Years-Old | \(>39\) Years-Old | Sig.         |
| Injection Site   | Injection Site Pain      | 186 (77.8%)        | 181 (77%)            | 0.834                  | 45 (71.4%)        | 41 (66.1%)   | 0.523                  |
|                  | Injection Site Swelling  | 45 (18.8%)         | 43 (18.3%)           | 0.882                  | 11 (17.5%)        | 9 (14.5%)    | 0.653                  |
|                  | Injection Site Redness   | 30 (12.6%)         | 21 (8.9%)            | 0.204                  | 5 (7.9%)          | 6 (9.7%)     | 0.731                  |
| Local SE         |                          |                    |                      |                       |                    |             |
| Intensity (\(\mu \pm SD\)) | 1.09 ± 0.83 | 1.04 ± 0.78 | 0.649 | 0.97 ± 0.78 | 0.90 ± 0.84 | 0.473 |
| Total            |                          | 188 (78.7%)        | 183 (77.9%)          | 0.835                  | 46 (73%)          | 42 (67.7%)   | 0.518                  |
| Fever            |                          | 24 (10%)           | 23 (9.8%)            | 0.926                  | 27 (42.9%)        | 33 (53.2%)   | 0.246                  |
| Chills           |                          | 35 (14.6%)         | 31 (13.2%)           | 0.648                  | 33 (52.4%)        | 39 (62.9%)   | 0.234                  |
| Headache/Fatigue |                          | 133 (55.6%)        | 95 (40.4%)           | 0.001                  | 45 (71.4%)        | 48 (77.4%)   | 0.443                  |
| Muscle Pain      |                          | 69 (28.9%)         | 64 (27.2%)           | 0.692                  | 33 (52.4%)        | 33 (53.2%)   | 0.925                  |
| Joint Pain       |                          | 45 (18.8%)         | 23 (9.8%)            | 0.005                  | 27 (42.9%)        | 32 (51.6%)   | 0.327                  |
| Nausea           |                          | 22 (9.2%)          | 17 (7.2%)            | 0.435                  | 15 (23.8%)        | 11 (17.7%)   | 0.403                  |
| Malaise          |                          | 48 (20.1%)         | 41 (17.4%)           | 0.462                  | 31 (49.2%)        | 30 (48.4%)   | 0.927                  |
| Lymphadenopathy  |                          | 27 (11.3%)         | 16 (6.8%)            | 0.089                  | 9 (14.3%)         | 4 (6.5%)     | 0.151                  |
| Systemic SE      |                          |                    |                      |                       |                    |             |
| Intensity (\(\mu \pm SD\)) | 1.69 ± 1.80 | 1.32 ± 1.69 | 0.006 | 3.49 ± 2.36 | 3.71 ± 2.15 | 0.592 |
| Total            |                          | 161 (67.4%)        | 128 (54.5%)          | 0.004                  | 53 (84.1%)        | 56 (90.3%)   | 0.300                  |
| Severe SE        |                          | 2 (0.8%)           | 0 (0%)               | 0.499 \(*\)           | 1 (1.6%)          | 3 (4.8%)     | 0.365 \(*\)          |
| Oral SE          |                          | 33 (13.8%)         | 26 (11.1%)           | 0.366                  | 26 (41.3%)        | 21 (33.9%)   | 0.393                  |
| Skin-related SE  |                          | 7 (2.9%)           | 7 (3%)               | 0.974                  | 2 (3.2%)          | 5 (8.1%)     | 0.273 \(*\)          |

Chi-squared test, Fisher’s exact test (*), and Mann–Whitney test were used with a significance level of <0.05.

### 3.8. Risk Factors of COVID-19 Vaccine Side Effects

On performing binary logistic regression for the demographic and medical risk factors, female gender (only for viral vector vaccine), the younger age group, chronic illnesses (only for viral vector vaccine), and medications were associated with an increased odds ratio (OR) of COVID-19 vaccine side effects, however not statistically significant. The previous infection statistically significantly increased OR of side effects for both vaccine types 21.310 for mRNA-based vaccine and 7.721 for viral vector-based vaccine.

Female participants were 3.429 times (CI 95%: 0.910–12.912) more likely to experience side effects after viral vector-based vaccine than their male counterparts. The participants with chronic illnesses and taking medications were 2.173 times (CI 95%: 0.571–8.270) and 3.6 times (CI 95%: 0.965–13.428) more likely to experience side effects after the viral vector-based vaccine (Table 9).

In the mRNA-based vaccine group, females had OR of 1.338 times (CI 95%: 0.881–2.032) for systemic side effects and OR of 1.021 times (CI 95%: 0.621–1.679) for local side effects. The younger age group had OR of 1.725 times (CI 95%: 1.188–2.505) for systemic side effects and OR of 1.047 times (CI 95%: 0.677–1.621) for local side effects. The chronic illnesses increased the OR for systemic side effects slightly; similarly, the medications increased the OR for local side effects slightly (Table 10).
Table 9. Risk Factors of COVID-19 Side Effects of German Healthcare Workers, February–March 2021 (n = 599).

| Predictor                  | mRNA-Based Vaccine | Viral Vector Vaccine | Total SE |
|----------------------------|--------------------|----------------------|----------|
|                            | OR (CI 95%)        | Sig.                 | OR (CI 95%) | Sig. | OR (CI 95%) | Sig. |
| Gender Female (vs. Male)   | 0.833 (0.441–1.573) | 0.573                | 3.429 (0.910–12.912) | 0.069 | 1.048 (0.603–1.819) | 0.869 |
| Age Group ≤ 39 years       | 1.141 (0.666–1.955) | 0.630                | 1.018 (0.279–3.705) | 0.979 | 1.122 (0.683–1.842) | 0.650 |
| Infection No (vs. Yes)     | 21.310 (2.180–208.303) | 0.009                | 7.721 (1.528–39.017) | 0.013 |
| Chronic Illness No (vs. Yes)| 0.911 (0.501–1.657) | 0.760                | 2.173 (0.571–8.270) | 0.255 | 1.058 (0.615–1.823) | 0.838 |
| Medical Treatment          | 1.032 (0.589–1.806) | 0.913                | 3.600 (0.965–13.428) | 0.057 | 1.281 (0.767–2.139) | 0.344 |

Table 10. Risk Factors of mRNA-based COVID-19 Vaccine Side Effects of German Healthcare Workers, February–March 2021 (n = 474).

| Predictor                  | Local SE | Systemic SE | Total SE |
|----------------------------|----------|-------------|----------|
|                            | OR (CI 95%) | Sig. | OR (CI 95%) | Sig. | OR (CI 95%) | Sig. |
| Gender Female (vs. Male)   | 1.021 (0.621–1.679) | 0.935 | 1.338 (0.881–2.032) | 0.172 | 0.833 (0.441–1.573) | 0.573 |
| Age Group ≤ 39 years       | 1.047 (0.677–1.621) | 0.835 | 1.725 (1.188–2.505) | 0.004 | 1.141 (0.666–1.955) | 0.630 |
| Infection No (vs. Yes)     | 11.100 (1.142–107.864) | 0.038 | 4.747 (0.490–45.986) | 0.179 | 21.310 (2.180–208.303) | 0.009 |
| Chronic Illness No (vs. Yes)| 0.863 (0.530–1.406) | 0.555 | 1.105 (0.739–1.654) | 0.626 | 0.911 (0.501–1.657) | 0.760 |
| Medical Treatment          | 1.084 (0.689–1.706) | 0.728 | 0.905 (0.614–1.333) | 0.613 | 1.032 (0.589–1.806) | 0.913 |

In the viral vector-based vaccine group, females had OR of 3.094 times (CI 95%: 1.061–9.022) for systemic side effects and OR of 2.677 times (CI 95%: 1.202–5.965) for local side effects. The participants with chronic illnesses had OR of 2.016 times (CI 95%: 0.667–7.094) for systemic side effects and OR of 1.182 times (CI 95%: 0.492–2.836) for local side effects. The participants taking medications regularly had OR of 2.125 times (CI 95%: 0.701–6.441) for systemic side effects and OR of 2.739 times (CI 95%: 1.162–6.455) for local side effects (Table 11).

Table 11. Risk Factors of Viral Vector-based COVID-19 Vaccine Side Effects of German Healthcare Workers, February–March 2021 (n = 125).

| Predictor                  | Local SE | Systemic SE | Total SE |
|----------------------------|----------|-------------|----------|
|                            | OR (CI 95%) | Sig. | OR (CI 95%) | Sig. | OR (CI 95%) | Sig. |
| Gender Female (vs. Male)   | 2.677 (1.202–5.965) | 0.016 | 3.094 (1.061–9.022) | 0.039 | 3.429 (0.910–12.912) | 0.069 |
| Age Group ≤ 39 years       | 1.289 (0.597–2.783) | 0.519 | 0.568 (0.193–1.671) | 0.304 | 1.018 (0.279–3.705) | 0.979 |
| Chronic Illness No (vs. Yes)| 1.182 (0.492–2.836) | 0.709 | 2.016 (0.667–6.094) | 0.214 | 2.173 (0.571–8.270) | 0.255 |
| Medical Treatment          | 2.739 (1.162–6.455) | 0.021 | 2.125 (0.701–6.441) | 0.183 | 3.600 (0.965–13.428) | 0.057 |
4. Discussion

This post-marketing study demonstrated that 88.1% of the surveyed German healthcare workers reported at least one side effect after receiving COVID-19 vaccines; 87.1% following mRNA-based vaccines and 92% following the viral vector-based vaccine.

The cross-vaccine comparison of our sample data revealed that mRNA-based vaccines were associated with more frequent local side effects (78.3% vs. 70.4%); while the viral vector-based vaccine was associated with more frequent systemic side effects (87.2% vs. 61%). The largest post-marketing study to date of COVID-19 vaccines analyzed the side effects of BNT162b2 (mRNA-based vaccine) and ChAdOx1 nCoV-19 (viral vector-based vaccine) reported by UK inhabitants using the COVID-19 Symptom Study app (ZOE Global, London, UK) [29,30]. Our results are consistent with the findings of this UK study; as the mRNA-based vaccine was associated with a higher prevalence of local side effects (71.7% vs. 58.7%), while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (33.7% vs. 20%) among the British population [30]. Similarly, Mathioudakis et al., 2021 found that local side effects were more frequent in the mRNA-based vaccine group, while the systemic side effects were more frequent in the viral vector-based vaccine group [31]. Abu-Hammad et al., 2021 found that the mRNA-based vaccine was significantly associated with local side effects, while the viral vector-based vaccine was associated with systemic side effects among Jordanian healthcare workers [32]. On the contrary, Alhazmi et al., 2021 found no significant difference in terms of local side effects among vaccinated individuals in Saudi Arabia; however, the viral vector-based vaccine was still significantly associated with an increased risk of systemic side effects [33].

While the vast majority of governments rely on more than one vaccine in their mass-vaccination strategies, there is a lack of evidence on the comparative side effects of different COVID-19 vaccines [34,35]. The current evidence is limited by a series of constraints, including unequal sample size across the study groups, lack of normal distribution of demographic and medical risk factors across the study groups, and lack of attention to the onset of each side effect [30–33,36]. Vaccine selectivity can be defined as “the discriminatory attitudes towards certain types of vaccines based on their target contagion or manufacturing technology that yields heterogeneous acceptance levels of recommended vaccines”. Understandably, public health researchers might be diverted from comparing the side effects of different COVID-19 vaccines to avoid triggering vaccine selectivity through misinterpretation of their results. Nevertheless, the infodemic related to vaccine safety has been pragmatically targeting specific types of COVID-19 vaccines to increase vaccine hesitancy or trigger public selectivity against these vaccines [37,38]. Therefore, it is imperative to expand in the cross-vaccine comparison research while sticking to the highest standards of epidemiologic methodology to synthesize rigorous evidence that should fairly inform the public and individuals’ decision of vaccination.

The younger age (≤39 years-old) group were 1.122 times (CI 95%: 0.683–1.842) more likely to experience side effects compared to the older age (>39 years-old) group. The age-related differences in our sample were only statistically significant in case of systemic side effects that affected the mRNA-based vaccine recipients (67.4% vs. 54.5%; Sig. = 0.004). Nonetheless, the older age group had more systemic side effects following viral vector-based vaccine than the younger group. Menni et al., 2021 found that the British individuals aged 55 years or below had significantly higher prevalence of side effects following both mRNA-based and viral vector-based vaccines [30]. Similarly, Jordanian healthcare workers (≤45 years-old) and UAE inhabitants (≤49 years-old) reported more side effects following COVID-19 vaccination [32,39]. Mazur et al., 2021 found that the incidence of post-vaccination oral side effects decreases in the older age groups among the included European healthcare workers [36]. In Czech Republic and Turkey, the younger healthcare workers reported a higher incidence of short-term side effects following BNT162b2 and CoronaVac vaccines, respectively, compared to their older colleagues [20,22]. In contrast to the supposition that “the younger you are, the more likely to experience side effects”, El-Shitany et al., 2021 found that the Saudi individuals aged 60 years or above had a
significantly higher level of local side effects, especially injection site pain (80.8% vs. 68.6%; Sig. = 0.0056) compared to their younger counterparts who received BNT162b2 vaccine [40]. The increased odds of side effects among young adults can be explained by the fact that these side effects are a by-product of the exuberant production of type I interferon (IFN-I) that occurs to initiate an effective immune response to the invading pathogen [41]. The generation of IFN-I in females and younger adults was found to be more potent [41,42]. The pre-marketing (phase III) and post-marketing (phase IV) studies of COVID-19 vaccines used heterogeneous cut-off points for the age-related analyses of vaccines reactogenicity and side effects. While the phase III trials used the retirement age cut-offs, e.g., 55 years-old and 65 years-old, some phase IV studies were inclined to use the median age of their own surveyed samples in order to compare the prevalence of post-vaccination side effects [20,30,40]. Both approaches are unequivocally effective in evaluating and communicating age-related differences; nevertheless, harmonizing vaccine safety reports, especially those from independent institutions, became a methodological must. Therefore, the findings of this study call for developing consensus guidelines for reporting COVID-19 vaccine side effects and effectiveness.

Female participants in our study had OR of 0.833 (CI 95%: 0.441–1.573) and 3.429 (CI 95%: 0.910–12.912) to experience side effects following mRNA-based vaccines and viral vector-based vaccine, respectively, thus indicating that viral vector-based vaccines impact females more significantly, while mRNA-based vaccines had no statistically significant lower OR in females. We can hypothesize that if an optimal sample size was reached for the viral vector-based vaccine this result would be more likely also statistically significant. Interestingly, all side effects were more common among female recipients of viral vector-based vaccine except injection site redness and lymphadenopathy, which were slightly more common among male recipients. Alghamdi et al., 2021 found within a viral vector-based vaccine recipients sample that the prevalence of post-vaccination side effects was significantly higher in females than males [43]. They also found that the onset of side effects occurrence is faster in females, and also the intensity of side effects and the rate of pain killer consumption were significantly higher in females [43]. The female predominance was also reported in mRNA-based vaccines and inactivated virus vaccines [20,22,40].

The more vigorous immune response and the lower pain threshold of females are suggested hypotheses to explain the gender-based differences in self-reported COVID-19 vaccines side effects [44,45]. The selection bias and the information bias may also play a key role in the emergence of gender-based differences; therefore, gender-adjusted analyses are indispensable in studying the self-reported outcomes of COVID-19 vaccines. Females were consistently associated with an increased risk of side effects following viral vaccines, including influenza, measles–mumps–rubella combination vaccine (MMR), attenuated Japanese encephalitis, and attenuated Dengue vaccines [44,46]. Future research should focus on the gender-based differences of COVID-19 vaccines side effects.

Injection site pain was the most prevalent local side effect in our sample (75.6%), followed by injection swelling (18%) and injection site redness (10.4%). The same order was found in both vaccines, the UK, Jordan, Saudi Arabia, and the Czech Republic [20,30,32,40]. In general, all the systemic side effects were significantly more common among viral vector-based vaccine recipients than mRNA-based vaccine recipients.

The most common systemic side effect among our mRNA-based vaccine recipients was headache/fatigue (48.1%), followed by muscle pain (28.1%), malaise (18.8%), joint pain (14.3%), chills (13.9%), and fever (9.9%). In the safety report of the Centers for Disease Control and Prevention (CDC) for BNT162b2 vaccine, headache/fatigue (44.1%) was the most common systemic side effect reported by the phase III volunteers, followed by muscle pain (25.4%), chills (19.7%), joint pain (15%), and fever (7.9%) [24]. The CDC report of mRNA-1273 vaccine revealed that headache/fatigue (47.8%) was the most common systemic side effect, followed by muscle pain (40%), joint pain (29%), chills (25.3%), and fever (7.9%) [25]. The prevalence of mRNA-based vaccine systemic side effects in our sample was lower than what was reported in the phase III trials [24,25]. The similar finding
was reported by the UK study were the side effects prevalence among the app user being significantly lower than the manufacturers’ reports [30]. Contrarily, Riad et al., 2021 found that the post-marketing prevalence of BNT162b2 side effects among Czech healthcare workers was higher than what was reported by the manufacturer [20].

The most common systemic side effect among our viral vector-based vaccine recipients was headache/fatigue (74.4%), followed by chills (57.6%), muscle pain (52.8%), malaise (48.8%), fever (48%), and joint pain (47.2%). In the safety report of the European Medicines Agency (EMA) for ChAdOx1 nCoV-19 vaccine, headache (52.7%), fatigue (53%), malaise (44.4%), muscle pain (43.9%), fever (41.1%), chills (32.2%), and joint pain (26.6%) [26]. The increased prevalence of side effects among our sample can be explained by the fact that the frequency of ChAdOx1 nCoV-19 side effects decreases after the second dose while our sample participants received only the first dose [26].

Manfredi et al., 2021 reported a case of a middle-aged female recipient of BNT162b2 vaccine who presented to their clinic with diffuse ulcerative lesions on the floor of the mouth associated with angular cheilitis and erythema of the tongue after two days of her first dose [47]. Poly(ethylene glycol) (PEG) as a constituent component of the mRNA-based vaccine was suspected to trigger these oral side effects [47,48]. Azzi et al., 2021 reported another case of a middle-aged female recipient of ChAdOx1 nCoV-19 with diffuse, erythematous and swollen red lesions on her buccal mucosa, tongue, gingiva and palate [49]. Heterozygous Factor V Leiden mutation was suspected to be the trigger of the thromboembolic events that were experienced by the patient, in addition to being a predisposing factor for the oral mucositis episode that followed the COVID-19 vaccination [49,50]. Oral mucosal lesions were increasingly reported in COVID-19 patients in the last months; therefore, the oral side effects of COVID-19 vaccines may mimic the COVID-19-associated oral symptoms [51–59].

In our sample, 17.7% of the participants reported at least one oral side effect, with mucosal lesions being the most commonly reported side effects, followed by bleeding gingiva (4.3%), halitosis (3.7%), and oral parasthesia (2.2%), and taste disturbance (2%). It is worthy of mentioning that oral parasthesia and taste disturbance were not solicited in our original questionnaire, even though the participants reported it voluntarily in the additional comment boxes. Therefore, we suggest that the actual prevalence of oral parasthesia and taste disturbance can be higher than what we report in this study. The participants referred to oral parasthesia by keywords, such as tongue tingling, mouth-tingling, and pins and needles sensation, e.g., while they referred to the taste disturbance by keywords like metallic taste, taste change, salty taste, and unpleasant taste, etc.

A large registry-based study by McMahon et al., 2021 revealed that mRNA-based vaccines were associated with a myriad of skin-related side effects that mimicked the SARS-CoV-2 infection [60]. In our sample 17 (2.8%) participants reported experiencing rash after vaccination, 4 (0.7%) reported urticaria, and 4 (0.7%) reported angioedema. The most common location of skin-related side effects was face (57.1%), followed by upper limb (38.1%), and lower limb (19%). However, there is a paucity of focus on the less common side effects, such as skin-related side effects by the phase IV trials of COVID-19 vaccines, and there is an emerging number of individual case reports and case series for recently vaccinated individuals with skin-related side effects [61].

**4.1. Strengths**

This is the first study to evaluate the side effects of COVID-19 vaccines among the German population to the best of the authors’ knowledge. This study is one of the few studies that aims to enhance our emerging knowledge about the risk factors of COVID-19 vaccines side effects by inquiring and analyzing the self-reported side effects across various demographic and medical parameters [20–22,30,31,40,62].

Another contribution of this study is its focus on the less reported side effects, e.g., the oral and skin-related ones, which were not solicited in the manufacturers’ reports of the phase III trials. However, the less common side effects being mild to moderate, may act as a
trigger for a vaccine hesitancy or vaccine resistance position by the vaccinated individuals or their household and acquaintances because they were not clearly explained a priori. The optimal sample size was reached for a total number of participants and for participants with Pfizer-BioNTech vaccine.

4.2. Limitations

The first limitation of this study is that the vast majority of viral vector-based vaccine recipients received only the first dose by the time they filled in the questionnaire; therefore, it was not possible to compare between the first and the second dose side effects. However, this corresponds with the public health strategy to extend the period between the first and second dose, especially among viral vector-based vaccines. Another limitation is because we did not ask about the timing of each inquired side effect, whether it was after the first dose, second dose, or both doses. The software used for data collection, KoBoToolbox, does not enable the researchers to learn the number of form visitors (potential respondents) which is the denominator of the response rate equation; therefore, we could not calculate the response rate in our study.

While this study, like typical post-marketing (phase IV) trials, relies primarily on the self-reported outcomes of the respondents, it had targeted healthcare workers as they are deemed to retain substantial levels of health literacy. The optimal sample size was not reached for the number of participants with Moderna and AstraZeneca-Oxford vaccines. This limitation should be seen in the context of the national vaccination strategy that limited the number of healthcare workers who received Moderna and AstraZeneca-Oxford vaccines.

4.3. Implications

This study implies that future research of COVID-19 vaccine safety should focus on cross-vaccine comparison as it can deliver timely and critical messages to the public. The findings of this study strengthen the call for consensus guidelines for reporting the independent studies of COVID-19 reactogenicity and side effects to overcome the growing heterogeneity among the reports of different research groups worldwide.

The age and gender-related differences of local and systemic side effects prevalence and incidence warrant further investigation. The less common side effects, e.g., oral and skin-related side effects, should be widely tracked by independent vaccine safety studies. The onset of each side effect and its duration should be precisely inquired about in future vaccine safety studies.

The findings of this study serve as independent evidence on the safety of COVID-19 vaccines that should encourage the public to take informed decisions for getting vaccinated, as the non-serious side effects we found were of limited duration (1–3 days), mainly related to the injection site and not interfering with the daily routine.

5. Conclusions

Overall, 88.1% of the German healthcare workers included in this study reported at least one side effect following the COVID-19 vaccination. The mRNA-based vaccines were associated with a higher prevalence of local side effects, while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects. Females and the younger age group were associated with an increased risk of side effects either after mRNA-based or viral vector-based vaccines. The gender- and age-based differences warrant further rigorous investigation and standardized methodology. Injection site pain was the most common local side effect, and headache/fatigue, muscle pain, malaise, chills, and joint pain were the most common systemic side effects. More than one-sixth of the participants reported at least one oral side effect, including mucosal lesions, oral paresthesia, and taste disturbance. The vast majority (84.9%) of side effects resolved within 1–3 days after vaccination, which is a positive message to the public about the short-term safety of vaccines.

Author Contributions: Conceptualization, A.R. and M.K.; methodology, M.K., A.R. and S.A.; validation, M.M., J.C. and S.A.; formal analysis, A.R.; investigation, M.M., J.C., M.B. and S.A.; writing—
original draft preparation, A.R. and S.A.; writing—review and editing, M.K. and H.-P.H.; supervision, M.K.; project administration, A.R.; funding acquisition, H.-P.H. and S.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by Masaryk University, grants number MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.R. and M.K. was supported by the INTER-EXCELLENCE grant number LTC20031—“Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic”.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Justus Liebig University of Giessen Ref. 55/20 on 27 January 2021.

**Informed Consent Statement:** Informed consent was obtained from all participants involved in the study.

**Data Availability Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Acknowledgments:** This work is dedicated to the more than ninety thousand fatalities and their families who have fallen victim to COVID-19 in Germany.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Attia, S.; Howaldt, H.-P. Impact of COVID-19 on the Dental Community: Part I before Vaccine (BV). *J. Clin. Med.* **2021**, *10*, 288. [CrossRef]

2. Leidner, A.J.; Murthy, N.; Chesson, H.W.; Biggerstaff, M.; Stoecker, C.; Harris, A.M.; Acosta, A.; Dooling, K.; Bridges, C.B. Cost-effectiveness of adult vaccinations: A systematic review. *Vaccine* **2019**, *37*, 226–234. [CrossRef] [PubMed]

3. Gavi the Vaccine Alliance. There are Four Types of COVID-19 Vaccines: Here’s How They Work. #VaccinesWork. Available online: https://www.gavi.org/vaccineswork/there-are-four-types-covid-19-vaccines-heres-how-they-work (accessed on 29 July 2021).

4. European Medicines Agency (EMA). Authorised COVID-19 Vaccines. COVID-19. Available online: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section (accessed on 29 July 2021).

5. Bettini, E.; Locci, M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. *Vaccines* **2021**, *9*, 147. [CrossRef] [PubMed]

6. Dong, Y.; Dai, T.; Wei, Y.; Zhang, L.; Zheng, M.; Zhou, F. A systematic review of SARS-CoV-2 vaccine candidates. *Signal Transduct. Target. Ther.* **2020**, *5*, 237. [CrossRef]

7. Divya, S.; Fahima Sheerin, S.M.H.; Chindhiha, S.; Selvakumar, K. Worldmeter Coronavirus Update (Live). *Int. J. Recent Acad. Res.* **2020**, *2*, 610–614. [CrossRef]

8. (RKI) RKI. Fallzahlen in Deutschland und Weltweit. Available online: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html (accessed on 7 July 2021).

9. Paul-Ehrlich-Institut. Coronavirus und COVID-19. Published 2021. Available online: https://www.pei.de/DE/newsroom/dossier/coronavirus/coronavirus-inhalt.html (accessed on 7 July 2021).

10. (MoH) B für G. COVID-19 Impfdashboard. Published 2021. Available online: https://impfdashboard.de/ (accessed on 7 July 2021).

11. Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. How Should Access to a COVID-19 Vaccine Be Regulated? Available online: https://www.ethikrat.org/fileadmin/Publikationen/Ad-hoc-Empfehlungen/englisch/joint-position-paper-stiko-der-leopoldina-vaccine-prioritisation.pdf (accessed on 3 July 2021).

12. Nohl, A.; Afflerbach, C.; Lurz, C.; Brune, B.; Ohmann, T.; Weichert, V.; Zeiger, S.; Dudda, M. Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany. *Vaccines* **2021**, *9*, 424. [CrossRef] [PubMed]

13. Bauerfeind, S.; Hitzenbichler, F.; Huppertz, G.; Zeman, F.; Koller, M.; Schmidt, B.; Plenzt, A.; Bauswein, M.; Mohr, A.; Salzberger, B. Brief report: Attitudes towards Covid-19 vaccination among hospital employees in a tertiary care university hospital in Germany in December 2020. *Infection* **2021**, *1*, 1–5. [CrossRef]

14. MacDonald, N.E.; Eskola, J.; Liang, X.; Chaudhuri, M.; Dube, E.; Gellin, B.; Goldstein, S.; Larson, H.; Manzo, M.L.; Reingold, A.; et al. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* **2015**, *33*, 4161–4164. [CrossRef] [PubMed]

15. KoBoToolbox.org. Harvard Humanitarian Initiative. Published 2020. Available online: https://support.kobotoolbox.org/welcome.html (accessed on 15 August 2020).

16. Riad, A. Oral Side Effects of COVID-19 Vaccine (OSECV). ClinicalTrials.gov. Published online 12 January 2021. Available online: https://clinicaltrials.gov/ct2/show/NCT04706156 (accessed on 24 February 2021).
17. Riad, A. Oral side effects of COVID-19 vaccine. *Br. Dent. J.* 2021, 230, 59. [CrossRef]
18. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gotzsche, P.C.; Vandenbroucke, J.P. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Bull. World Health Organ.* 2007, 85, 867–872. [CrossRef]
19. Centers for Disease Control and Prevention (CDC). Population Survey or Descriptive Study. StatCalc/User Guide. Available online: https://www.cdc.gov/epiinfo/user-guide/statcalc/samplesize.html (accessed on 19 May 2021).
20. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, J.; Koščík, M.; Klugar, M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. *J. Clin. Med.* 2021, 10, 1428. [CrossRef] [PubMed]
21. Riad, A.; Pokorná, A.; Mekhemar, M.; Conrad, J.; Klugarová, J.; Koščík, M.; Klugar, M.; Attia, S. Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. *Vaccines* 2021, 9, 673. [CrossRef]
22. Riad, A.; Sağrul, D.; Üstün, B.; Pokorná, A.; Klugarová, J.; Attia, S.; Klugar, M. Prevalence and Risk Factors of Coronavirus Vaccine Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. *J. Clin. Med.* 2021, 10, 2629. [CrossRef]
23. German Healthcare Statistics—VisaGuide.World. Available online: https://visaguide.world/international-health-insurance/germany/healthcare-statistics/ (accessed on 8 July 2021).
24. Centres for Diseases Control and Prevention (CDC). Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed on 2 April 2021).
25. Centres for Diseases Control and Prevention (CDC). Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html (accessed on 2 April 2021).
26. European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca. Available online: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-preciously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (accessed on 6 July 2021).
27. Proton Technologies AG. General Data Protection Regulation (GDPR) Compliance Guidelines. HORIZON 2020—Project REP-791727-1. Published 2020. Available online: https://gdpr.eu/ (accessed on 1 May 2020).
28. SPSS Inc. IBM SPSS Statistics 27. Published 14 October 2020. Available online: https://www.ibm.com/support/pages/node/306603 (accessed on 14 March 2021).
29. Menni, C.; Valdes, A.M.; Freidin, M.B.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Ganesh, S.; Varsavsky, T.; Cardoso, M.J.; Moustafa, J.S.E.-S.; et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat. Med.* 2020, 26, 1037–1040. [CrossRef]
30. Menni, C.; Klaser, K.; May, A.; Polidori, L.; Capdevila, J.; Louca, P.; Sudre, C.H.; Nguyen, L.H.; Drew, D.A.; Merino, J.; et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. *Lancet. Infect. Dis.* 2021, 21, 939–949. [CrossRef]
31. Mathioudakis, A.G.; Ghrew, M.; Ustianowski, A.; Ahmad, S.; Borrow, R.; Papavasileiou, L.P.; Petrakis, D.; Bakerly, N.D. Self-reported real-world safety and reactogenicity of covid-19 vaccines: A vaccine recipient survey. *Life* 2021, 11, 249. [CrossRef]
32. Abu-Hammad, O.; Alduraidi, H.; Abu-Hammad, S.; Alnazzawi, A.; Babkair, H.; Abu-Hammad, A.; Nourwali, I.; Qasem, F.; Dar-Odeh, N. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. *Vaccines* 2021, 9, 577. [CrossRef]
33. Alhazmi, A.; Alamer, E.; Dawes, D.; Hakami, M.; Darraj, M.; Abdelwahab, S.; Maghufi, A.; Algaissi, A. Evaluation of Side Effects Associated with COVID-19 Vaccine in Saudi Arabia. *Vaccines* 2021, 9, 674. [CrossRef] [PubMed]
34. Gavi—The Vaccine Alliance. Immunisation: Strengthening Primary Healthcare for Universal Health Coverage Immunisation-a Platform for Strengthening Primary Health Care. Available online: www.gavi.org (accessed on 1 July 2021).
35. World Health Organization (WHO). COVID-19 Vaccines. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed on 3 July 2021).
36. Mazur, M.; Duś-Ilnicka, I.; Jedliński, M.; Nدokaj, A.; Janiszewska-Olszowska, J.; Ardan, R.; Radwan-Oczko, M.; Guerra, F.; Luzzi, V.; Vozza, I.; et al. Facial and Oral Manifestations Following COVID-19 Vaccination: A Survey-Based Study and a First Perspective. *Int. J. Clin. Med.* 2021, 10, 85, 249. [CrossRef]
37. Montagni, I.; Ouazzani-Touhami, K.; Mebarki, A.; Texier, N.; Schück, S.; Tzourio, C.; the CONFINS Group. Acceptance of a COVID-19 Vaccine is associated with ability to detect fake news and health literacy. *J. Public Health* 2021, fdab028. [CrossRef]
38. Boytchev, H. Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people—without evidence? *BMJ* 2021, 372, n414. [CrossRef] [PubMed]
39. Saeed, B.Q.; Al-Shahrabi, R.; Alhajj, S.S.; Alkkohardi, Z.M.; Adrees, A.O. Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination. *medRxiv* 2021. [CrossRef]
40. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.G.; Almukadi, H.S.; Alghamdi, B.S.; Alamhd, A.A.; Hassan, N.A.; Sindi, N.; et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. *Int. J. Gen. Med.* 2021, 14, 1389–1401. [CrossRef]
41. Sprent, J.; King, C. COVID-19 vaccine side effects: The positives about feeling bad. *Sci. Immunol.* 2021, 6, eabj9256. [CrossRef] [PubMed]
42. Bunders, M.J.; Altfield, M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity* 2020, 53, 487–495. [CrossRef]
43. Alghamdi, A.; Ibrahim, A.; Almutairi, R.; Joseph, M.; Alghamdi, G.; Alhamza, A. A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: Male versus female outcomes. *J. Adv. Pharm. Educ. Res.* 2021, 11, 51–56. [CrossRef]

44. Klein, S.L.; Jedlicka, A.; Pekosz, A. The Xs and Y of immune responses to viral vaccines. *Lancet Infect. Dis.* 2010, 10, 338–349. [CrossRef]

45. Bartley, E.J.; Fillingim, R.B. Sex differences in pain: A brief review of clinical and experimental findings. *BJA Br. J. Anaesth.* 2013, 111, 52. [CrossRef] [PubMed]

46. Klein, S.L.; Pekosz, A. Sex-based biology and the rational design of influenza vaccination strategies. *J. Infect. Dis.* 2014, 209, S114. [CrossRef] [PubMed]

47. Manfredi, M.; Ghidini, G.; Ridolo, E.; Pizzi, S. Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine. *Oral Dis.* 2021. [CrossRef] [PubMed]

48. Sellaturay, P.; Nasser, S.; Islam, S.; Gurugama, P.; Ewan, P.W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin. Exp. Allergy* 2021, 51, 861–863. [CrossRef] [PubMed]

49. Azzi, L.; Toia, M.; Stevanello, N.; Maggi, F.; Forlani, G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. *Oral Dis.* 2021. [CrossRef] [PubMed]

50. Zermatten, M.G.; Calderara, D.B.; Aliotta, A.; Alberio, L. Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report. *Res. Pract. Thromb. Haemost.* 2020, 4, 429–432. [CrossRef]

51. Riad, A.; Klugar, M.; Krsek, M. COVID-19 Related Oral Manifestations, Early Disease Features? *Oral Dis.* 2020. [CrossRef]

52. Hocková, B.; Riad, A.; Valky, J.; Šulajová, Z.; Stebel, A.; Slávik, R.; Bečková, Z.; Pokorná, A.; Klugarová, J.; Klugar, M. Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases. *J. Clin. Med.* 2021, 10, 581. [CrossRef] [PubMed]

53. Riad, A.; Gad, A.; Hockova, B.; Klugar, M. Oral candidiasis in non-severe COVID-19 patients: Call for antibiotic stewardship. *Oral Surg.* 2020, 12561. [CrossRef]

54. Riad, A.; Gomaa, E.; Hockova, B.; Klugar, M. Oral Candidiasis of COVID-19 Patients: Case Report and Review of Evidence. *J. Cosmet. Dermatol.* 2021, 20, 1580–1584. [CrossRef] [PubMed]

55. Riad, A.; Kassem, I.; Badrah, M.; Klugar, M. The manifestation of oral mucositis in COVID-19 patients: A case-series. *Dermatol. Ther.* 2020, 33, e14479. [CrossRef]

56. Al-Khanati, N.M.; Riad, A.; Sahloul, M.E.; Klugar, M. Aphthous-like stomatitis of COVID-19 patients. *Braz. J. Oral Sci.* 2020, 19, e201354. [CrossRef]

57. Riad, A.; Kassem, I.; Stanek, J.; Badrah, M.; Klugarová, J.; Klugar, M. Aphthous Stomatitis in COVID-19 Patients: Case-series and literature review. *Dermatol. Ther.* 2021, 34, e14735. [CrossRef]

58. Riad, A.; Kassem, I.; Issa, I.; Badrah, M.; Klugar, M. Angular cheilitis of COVID-19 patients: A case-series and literature review. *Oral Dis.* 2020, 13675. [CrossRef]

59. Riad, A.; Kassem, I.; Hockova, B.; Badrah, M.; Klugar, M. Halitosis in COVID-19 patients. *Spec. Care Dent.* 2021, 41, 282–285. [CrossRef] [PubMed]

60. McMahon, D.E.; Amerson, E.; Rosenbach, M.; Lipoff, J.B.; Moustafa, D.; Tyagi, A.; Desai, S.R.; French, L.E.; Lim, H.W.; Thiers, B.H.; et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. *J. Am. Acad. Dermatol.* 2021, 85, 46–55. [CrossRef] [PubMed]

61. Gronbeck, C.; Grant-Kels, J.M. Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them! *Clin. Dermatol.* 2021. [CrossRef]

62. Kadali, R.A.K.; Janagama, R.; Peruru, S.; Gajula, V.; Madathala, R.R.; Chennaiahgari, N.; Malayala, S.V. Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. *J. Med. Virol.* 2021, 93, 4420–4429. [CrossRef]